Ovarian cancer extracellular vesicle biomarkers

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2024-10-20 DOI:10.1016/j.cca.2024.120011

Zeinab Jamali , Masoumeh Razipour , Mahsa Zargar , Hojat Ghasemnejad-Berenji , Seyed Mohammad Akrami

引用次数: 0

Abstract

Ovarian cancer (OC) remains a significant women’s health concern due to its high mortality rate and the challenges posed by late detection. Exploring novel biomarkers could lead to earlier, more specific diagnoses and improved survival rates for OC patients. This review focuses on biomarkers associated with extracellular vesicles (EVs) found in various proximal fluids, including urine, ascites, utero-tubal lavage fluid of OC patients. We highlight these proximal fluids as rich sources of potential biomarkers. The review explains the roles of EV biomarkers in ovarian cancer progression and discusses EV-related proteins and miRNAs as potential diagnostic or prognostic indicators and therapeutic targets. Finally, we highlighted the limitations of examining proximal fluids as sources of biomarkers and encourage researchers to proactively pursue innovative solutions to overcome these challenges.

查看原文本刊更多论文

卵巢癌细胞外囊泡生物标志物。

由于卵巢癌（OC）的高死亡率和晚期检测带来的挑战，它仍然是妇女健康的一个重大问题。探索新型生物标志物可使卵巢癌患者得到更早、更具体的诊断，并提高生存率。本综述重点研究与卵巢癌患者尿液、腹水、子宫输卵管灌洗液等各种近端体液中发现的细胞外囊泡 (EV) 相关的生物标记物。我们强调这些近端体液是潜在生物标记物的丰富来源。综述解释了EV生物标志物在卵巢癌进展中的作用，并讨论了作为潜在诊断或预后指标和治疗靶点的EV相关蛋白和miRNA。最后，我们强调了将近端体液作为生物标志物来源进行研究的局限性，并鼓励研究人员积极寻求创新的解决方案来克服这些挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.